Drug Trial Radar · NCT06117540
A Study of WX390 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
70
Planned (sponsor's estimate)
Start
May 11, 2021
Primary completion
Jun 12, 2025
Study completion Jun 12, 2026
Sponsor
- Lead sponsor
- Shanghai Jiatan Pharmatech Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the efficacy and safety of WX390 in patients with advanced solid tumors. The main questions it aims to answer are: * PFS, OS, DoR at week 48; * antitumor effects at week 24 and week 48. Participants will be treated with WX390 orally, and follow the efficacy and safety evaluation according to the protocol.
Conditions
- Solid Tumor
Interventions
WX390Drug
WX390 tablet, 1.1 mg once a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: Week 48
- Overall Survival (OS)Time frame: Week 48
- Duration of Response (DOR)Time frame: Week 48
- Progression-free survival rate (PFSR)Time frame: Week 24 and Week 48
- Objective Response Rate (ORR)Time frame: Week 24 and Week 48
- Disease control rate (DCR)Time frame: Week 24 and Week 48
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.